Navamedic launches Eroxon[®] in Finland
Oslo, 6 November 2024 – Building on the successful product launch of Eroxon® in Norway and Sweden earlier this year, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, is now launching Eroxon® across pharmacies in Finland. Eroxon® will be the first clinically proven over-the-counter topical treatment for the treatment of erectile dysfunction in men in Finland.
Eroxon® is part of Navamedic’s increasingly growing Consumer Health category. Since the product launched in Norway in February 2024, Eroxon® has already become one of the top performing products within this category, and it is expected to continue driving further growth. The product launch in Finland marks the third launch this year and will be followed by a launch in Denmark in 2025.
The Finnish market for erectile dysfunction has significant potential. A recent study [1] concluded that 37 per cent of Finnish men above 18 years of age, more than 800,000 men, have had first-hand experience with erectile dysfunction. Two in three of these men had previously sought help to medically treat the condition, indicating that men in Finland have a higher willingness to treat the condition than their neighbours in other Nordic countries.
“Eroxon® is a fast-acting, safe, and easily accessible product designed to help men enhance their sexual health and overall quality of life. With a significant number of men in Finland experiencing erectile dysfunction and showing interest in effective treatment options, we see strong market potential for Eroxon® in supporting their health and well-being,” said Jack Spira, Medical Director at Navamedic.
Eroxon® offers a range of features which differentiates it from other forms of treatments for erectile dysfunction. It is an effective and fast-acting gel which typically helps men get an erection within ten minutes of application. It has a good safety profile due to its local effect with no systemic absorption. Eroxon® is approved as a treatment for erectile dysfunction in the EU and the US.
[1] About the study
A total of 1,576 Finns aged 18 and over responded to the Eroxon® survey, which was conducted in September-October 2024 (25/9–1/10/2024). The results are weighted to be representative of the population. The number of respondents varies by question. The survey was conducted by Taloustutkimus Oy. The maximum margin of error for the entire respondent population is +/- 2.7 percentage points.
